Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

128.46 +3.59 (+2.87%)
Streaming Delayed Price Updated: 10:01 AM EDT, May 17, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 31,611
Open 127.41
Bid (Size) 128.29 (2)
Ask (Size) 128.62 (2)
Prev. Close 124.87
Today's Range 126.82 - 130.10
52wk Range 117.58 - 212.00
Shares Outstanding 118,847,693
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Alnylam to Webcast Presentations at Upcoming May Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Why HC Wainwright Is Bullish On This Stock's Hepatitis-B Pipeline
 
Via Benzinga

Performance

YTD
-26.14%
-26.14%
1 Month
-18.01%
-18.01%
3 Month
-13.59%
-13.59%
6 Month
-25.88%
-25.88%
1 Year
-5.47%
-5.47%

More News

Read More
10 Biggest Price Target Changes For Monday
Via Benzinga
Expert Ratings for Alnylam Pharmaceuticals
Via Benzinga
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Via Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
Via Benzinga
Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
What To Know About Morgan Stanley's Downgrade of Alnylam Pharmaceuticals
Via Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Via Benzinga
See Why Did FDA Extend Review Period For Alnylam's Vutrisiran In Amyloidosis
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
Via Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
Via InvestorPlace
Alnylam Pharmaceuticals Q1 2022 Earnings Conference Call On April 28, 2022 At 08:30 AM ET
Via Benzinga
Alnylam to Webcast Conference Call Discussing First Quarter 2022 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Retirement of Steven Paul, M.D. from Board of Directors
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
Via Benzinga
Alnylam to Webcast Presentation at Stifel 2022 CNS Days
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
World Markets News For Friday
Via Talk Markets
Maker Of Pfizer's COVID-19 Vaccine mRNA-Delivery Tech Sues Arbutus Biopharma: Reuters
Via Benzinga
Alnylam Hits Pfizer, Moderna With Patent Infringement Suits
Via Benzinga
Alnylam Pharmaceuticals Files Patent Infringement Suits against Pfizer and Moderna
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Issues 2021 Corporate Responsibility Report
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
What 8 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.